Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $22.0 million.

  • Revolution Medicines' Change in Accured Expenses rose 340.56% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.0 million, marking a year-over-year increase of 3017.09%. This contributed to the annual value of $22.0 million for FY2024, which is 49.88% up from last year.
  • According to the latest figures from FY2024, Revolution Medicines' Change in Accured Expenses is $22.0 million, which was up 49.88% from $14.7 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Change in Accured Expenses peaked at $22.0 million during FY2024, and registered a low of $1.5 million during FY2022.
  • For the 3-year period, Revolution Medicines' Change in Accured Expenses averaged around $12.7 million, with its median value being $14.7 million (2023).
  • As far as peak fluctuations go, Revolution Medicines' Change in Accured Expenses tumbled by 82.78% in 2022, and later skyrocketed by 876.56% in 2023.
  • Over the past 5 years, Revolution Medicines' Change in Accured Expenses (Yearly) stood at $4.9 million in 2020, then surged by 79.61% to $8.7 million in 2021, then crashed by 82.78% to $1.5 million in 2022, then soared by 876.56% to $14.7 million in 2023, then soared by 49.88% to $22.0 million in 2024.